Anti-TfR1 Oligonucleotide Complexes for Muscle-Targeted DMPK Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for myotonic dystrophy type 1 (DM1) are ineffective, and there is a need for targeted delivery of oligonucleotides to muscle cells to address the underlying genetic cause of the disease.
Innovation Solution
Development of muscle-targeting complexes comprising an oligonucleotide covalently linked to an anti-transferrin receptor 1 (TfR1) antibody, formulated with tris(hydroxymethyl)aminomethane and sucrose, for targeted delivery to muscle cells to reduce DMPK expression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If oligonucleotides are delivered systemically, then they can reach muscle cells, but they lack targeted delivery and accumulate in non-target tissues
Solution Approach 1:
The patent uses an anti-transferrin receptor antibody as an intermediary carrier to bind oligonucleotides and deliver them specifically to muscle cells that express high levels of transferrin receptor. This mediator enables targeted delivery while preventing random distribution and accumulation in non-target tissues.
Solution Approach 2:
The patent creates complexes with heterogeneous oligonucleotide-to-antibody ratios to optimize local delivery properties. The variable composition allows tailored targeting efficiency and reduced off-target effects in different tissue environments.
2Ease of manufacture
If oligonucleotide-to-antibody ratios are standardized, then manufacturing is simplified, but delivery efficiency varies across different applications
Solution Approach 1:
The patent systematically varies the oligonucleotide-to-antibody ratio as a key parameter to optimize delivery efficiency for different indications and routes of administration. This parameter optimization balances manufacturing complexity with therapeutic effectiveness.
Solution Approach 2:
The patent employs complexes with varying stoichiometries, including formulations with excess oligonucleotide or antibody, to achieve optimal delivery. This partial optimization approach allows flexibility in balancing manufacturing ease with delivery performance.
3Stability of the object's composition
If complex formulations are optimized for stability, then storage and handling are improved, but delivery kinetics may be affected
Solution Approach 1:
The patent optimizes formulation parameters including buffer composition (tris(hydroxymethyl)aminomethane), excipients (sucrose), and pH to achieve stable storage while maintaining delivery kinetics. The stabilized complexes retain their targeting functionality after storage.
Solution Approach 2:
The patent performs preliminary stabilization of the oligonucleotide-antibody complexes through optimized formulation before administration. This preliminary action ensures the complexes remain stable during storage and handling while preserving their delivery capability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The complexes effectively target and reduce DMPK expression in muscle tissues, demonstrating splicing correction and DMPK knockdown in animal models and patient-derived cells, providing a potential therapeutic approach for DM1.
Implementation Method 1
an anti-transferrin receptor 1 (TfR1) antibody
Data Source
AI summary
Aspects of the disclosure relate to complexes and other aspects relate to formulations (e.g., aqueous, lyophilized forms) comprising such complexes comprising an oligonucleotide (e.g., useful for targeting DMPK) covalently linked to an antibody (e.g., anti-TfR1 antibody).